Journal
NATURE REVIEWS RHEUMATOLOGY
Volume 9, Issue 3, Pages 173-182Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrrheum.2013.7
Keywords
-
Categories
Ask authors/readers for more resources
The molecular biology revolution coupled with the development of monoclonal antibody technology enabled remarkable progress in rheumatology therapy, comprising an array of highly effective biologic agents. With advances in understanding of the molecular nature of immune cell receptors came elucidation of intracellular signalling pathways downstream of these receptors. These discoveries raise the question of whether selective targeting of key intracellular factors with small molecules would add to the rheumatologic armamentarium. In this Review, we discuss several examples of this therapeutic strategy that seem to be successful, and consider their implications for the future of immune-targeted treatments. We focus on kinase inhibitors, primarily those targeting Janus kinase family members and spleen tyrosine kinase, given their advanced status in clinical development and application. We also summarize other targets involved in signalling pathways that might offer promise for therapeutic intervention in the future. O'Shea, J. J. etal. Nat. Rev. Rheumatol. 9, 173-182 (2013); published online 19 February 2013; doi:10.1038/nrrheum.2013.7
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available